MURANO-studie: venetoclax bij recidiverend/refractair CLL

Delen via:
ASH Annual Meeting 2017

Log hier in om volledige toegang te krijgen.

Login of Account maken

 

Bronnen:
Seymour JF, Kipps TJ, Eichhorst BF, et al. Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study. ASH 59th Annual Meeting & Exhibition, abstract LBA-2.